Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
Revenue (TTM)
$8 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.1 %
ROCE
-- %
P/E Ratio
0
P/B Ratio
1
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-236.2
Face value
--
Shares outstanding
17,226,400
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Azitra Inc (AZTR)
| -38.4 | -3.0 | -25.0 | -96.3 | -- | -- | -- |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
|---|---|
|
Azitra Inc (AZTR)
| -98.4 |
|
S&P Small-Cap 600
| 7.0 |
|
BSE Sensex
| 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Azitra Inc (AZTR)
|
0.3 | 4.6 | 7.5 | -3,074.4 | -146,429.4 | -139.2 | 0 | 1.0 |
| 2.2 | 3.1 | 0.7 | -10.3 | -1,278.2 | -203.6 | -- | 0.0 | |
| 0.7 | 162.9 | 1.0 | -155.9 | -15,251.5 | -- | -- | 0.0 | |
| 119.8 | 12,188.4 | 5,512.6 | 494.7 | 17.0 | 16.3 | 24.9 | 5.6 | |
| 1.2 | 200.2 | 0.0 | -3.3 | -- | -- | -- | 0.0 | |
| 7.5 | 218.0 | 7.0 | -20.0 | -271.4 | -13.4 | -- | 1.5 | |
| 2.6 | 24.1 | 2.9 | -8.4 | -181.0 | -- | -- | 94.8 | |
| 1.8 | 212.0 | 41.6 | -202.0 | -496.2 | -136.3 | -- | 2.0 | |
| 0.5 | 16.8 | 0.0 | -1.0 | -- | -12.4 | 5.4 | 1.8 | |
| 0.9 | 3.4 | 0.0 | -1.0 | -- | -40.9 | -- | 1.2 |
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S.... epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut. Address: 21 Business Park Drive, Branford, CT, United States, 06405 Read more
President, CEO & Director
Mr. Francisco D. Salva
President, CEO & Director
Mr. Francisco D. Salva
Headquarters
Branford, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Azitra Inc (AZTR) stood at $ 9,777 Mln as on 31-Mar-25
The share price of Azitra Inc (AZTR) is $0.26 (NYSE) as of 18-Jun-2025 16:21 EDT. Azitra Inc (AZTR) has given a return of -96.26% in the last 1 years.
Azitra Inc (AZTR) has a market capitalisation of $ 5 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Azitra Inc (AZTR) is 1.03 times as on 18-Jun-2025, a 72% discount to its peers’ median range of 3.62 times.
Since, TTM earnings of Azitra Inc (AZTR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Azitra Inc (AZTR) and enter the required number of quantities and click on buy to purchase the shares of Azitra Inc (AZTR).
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut. Address: 21 Business Park Drive, Branford, CT, United States, 06405
The CEO & director of Mr. Francisco D. Salva. is Azitra Inc (AZTR), and CFO & Sr. VP is Mr. Francisco D. Salva.
There is no promoter pledging in Azitra Inc (AZTR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
20
|
|
|
19
|
|
|
2
|
|
|
2
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
1,204
|
| Azitra Inc (AZTR) | Ratios |
|---|---|
|
Return on equity(%)
|
-139.25
|
|
Operating margin(%)
|
-146429.44
|
|
Net Margin(%)
|
-40991.73
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Azitra Inc (AZTR) was $0 Mln.
$0.00
(
